Pancreas cancer treatment: A surgeon's perspective today  by Coppola, Roberto
at SciVerse ScienceDirect
International Journal of Surgery 10 (2012) 187–189
INVITED EDITORIALContents lists availableInternational Journal of Surgery
journal homepage: www.thei js .comInvited editorial
Pancreas cancer treatment: A surgeon’s perspective todayqIn 1968 John Howard, one of the pioneers of pancreatic surgery,
reported the ﬁrst series of patients submitted to pancreatic resec-
tionwithout mortality. This contributed to reduce skepticism about
pancreas surgery and to open a new surgical era. Nowadays, perio-
perative mortality after pancreaticoduodenectomy in high-volume
centers does not exceed 2–3% of cases, and the goal of zero-
mortality surgery has been reached by some centers.1,2 These data
have an outstanding value, since safe surgical resection remains
the only potentially curative treatment for pancreas cancer.
In spite of this signiﬁcant improvement in mortality rates, peri-
operative morbidity still remains a major problem, especially in
patients undergoing pancreatic head resection. Even in high-
volume centers, the perioperative morbidity rate after pancreatico-
duodenectomy reaches 30% to 40%, without any trend toward
reduction.2 There is general agreement in the scientiﬁc community
that this high rate is signiﬁcantly correlated to the fact that the inci-
dence of pancreatic ﬁstula has not changed during the last ten
years. Despite many technical proposals concerning pancreas
remnant anastomosis and duct occlusion, and despite our better
knowledge of factors inﬂuencing the onset of pancreatic ﬁstula
(small pancreatic duct, soft pancreas), we are still unable to reduce
this serious complication. Perhaps there are factors that we do not
yet understand, and new ﬁelds of investigation must be explored.
With regard to this aim, a recent clinical trial3 shows that in
highly selected patients, early drainage removal compared to late
drainage removal is associated to a signiﬁcantly lower rate of
pancreatic ﬁstula and abdominal complications. Thus, a prolonged
period of drainage insertion seems to be an independent risk factor
for pancreatic ﬁstula in a selected group of patients. This interesting
study is a clear demonstration that the surgeon still has work to do.
1. Pancreaticoduodenectomy: radical or palliative procedure?
The growing importance of the pathological examination of
resection margins
Approximately one-third of patients undergoing pancreatico-
duodenectomy classiﬁed as “radical” (i.e. R0) develop local recur-
rence very soon after the operation. For many years this was
considered to be the surgeon’s fault, and so, in recent years, we
have sought to improve our surgical technique, especially in per-
forming retroduodenal margin (SMA margin) resection. Unfortu-
nately, this was not enough.
Resection margin involvement (R1) is a key prognostic factor
after pancreatic surgery,4 but the R1 rate reported in the literature
varies greatly, from 20% to 75%.5,6q This paper was not peer-reviewed.
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recurrence and rate of resection margin involvement (R1). In fact,
many centers report an incidence of local recurrence that is signif-
icantly higher than their rate of R1 resections. This remarkable
difference limits the scope for meaningful comparison and
precludes conclusions regarding the prognostic signiﬁcance of
resection margin status. But how can this discrepancy be
explained? Resection margin involvement is generally believed to
be determined by the quality of the surgery, with a lower R1 rate
being considered an indicator of higher quality surgery. However,
in recent years this concept has been criticized since studies have
brought the pathologist as a second player onto the scene.
Due to anatomical considerations regarding the head of the
pancreas (proximity of vessels and other organs), the resection
margins of pancreaticoduodenectomy cannot, in some cases, be
extended as would be necessary.
It is therefore evident that R1 rate is not necessarily ameasure of
the surgeon’s performance, but it is almost always a measure of the
performance of the pathologist. As a consequence it can be stated
that there is a growing awareness that standardization and metic-
ulousness of the pathological examination have a signiﬁcant impact
on the accuracy of the reported resection margin status.
In order to standardize the work of the pathologist a new
method of pathological evaluation of the specimen after pancreati-
coduodenectomy has been developed. This new method, ﬁrst
proposed by Verbeke,7 takes into consideration the three spatial
dimensions of the resected specimen, highlighting the importance,
as in other organs, of the new concept of “circumferential margins”.
The different margins are identiﬁed by a multicolor system and the
specimen is cut into several axial slices. In contrast to the generally
adopted deﬁnition of R0 for pancreatic head cancer (tumoral tissue
at 0 mm from the surgical margin), R0 is deﬁned as a tumor-free
margin of at least 1 mm.7
Several papers published in recent years have demonstrated
that the use of this new standardized method to manage the spec-
imen after pancreaticoduodenectomy leads to better staging and to
amore accurate evaluation of R status. Adopting this new approach,
R1 status is found in up to 80% of pancreas specimens.7 As a conse-
quence, we can assume that R0 resection for pancreas cancer is per-
formed in only a minority of cases. If conﬁrmed, this evidence will
signiﬁcantly impact the management of pancreatic cancer.2. Vessel involvement: how far should we go?
Vessel involvement is present at diagnosis in one-third of
cancers of the head or the body of the pancreas. To date, there is
general agreement that venous involvement alone (portal veind. All rights reserved.
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surgical resection, as is conﬁrmed by data collected in a systematic
review.8,9 Patients with venous involvement submitted to vascular
resection show good survival, and no increase in perioperative
morbidity or mortality.8
On the contrary, tumor inﬁltration of the superior mesenteric
artery or the celiac axis (encasement of more than 180) must still
be considered as unresectable disease. However, there is only
limited data in the literature to support this statement.10 Advances
in pancreatic surgery, with signiﬁcant improvement of patients’
perioperative outcome, and in the absence of effective alternative
therapeutic options, have therefore fueled an ongoing debate: are
more radical surgical approaches allowed, in patients without
metastases, in order to achieve tumor extirpation?
A large retrospective analysis,11 and more recently a meta-anal-
ysis,10 have been published on this topic. These papers provide
evidence that pancreaticoduodenectomy with concomitant arterial
resection is affected by poorer perioperative outcome and worse
long-term survival if compared with pancreaticoduodenectomy
alone or pancreaticoduodenectomy with venous resection.
However, long-term survival following pancreaticoduodenectomy
with arterial resection is superior to palliative treatment alone.
The Authors conclude that arterial vascular resection should be
undertaken only in highly selected patients, and should be per-
formed only in high-volume centers.
3. Neoadjuvant treatment: is this the future?
Poor oncological outcome after “radical” surgery has, in recent
years, increased the scientiﬁc community’s attention to neoadjuvant
treatment. Neoadjuvant treatment offers several advantages over
up-front surgery. One of these is the identiﬁcation of patients with
occult metastatic disease, who would not beneﬁt from
surgical resection and could be spared the risks of an unnecessary
operation.12,13
A second possible advantage is the reduction of microscopically
positive margins after surgery.14 Almost all patients who receive
neoadjuvant therapies are able to complete treatment, whereas
25% of patients who undergo up-front surgery are unable to
complete adjuvant therapy.
In evaluating these advantages of neoadjuvant treatment it is
useful to divide patients into two groups: patients with initially
resectable tumor, and patients with advanced tumor.
For patients with initially resectable tumors, the putative advan-
tages of neoadjuvant therapy seem to be very promising. For this
reason, recent consensus guidelines recommend that this approach
should be put into common practice.15 The logic is that neoadjuvant
therapywill yieldbeneﬁts forpatientswhoprogressduring the treat-
mentperiodby sparing themanunnecessary surgical intervention. A
speciﬁc argument to support chemoradiation before surgery for
patients with initially resectable tumors is that this therapy would
achieve better local control of thedisease, leading to a higher propor-
tion of patients with R0 resection. However, since the deﬁnition of
margin status is not consistent between different trials or different
institutions, there is no clear evidence of this possible beneﬁt.
A further hypothetical beneﬁt of neoadjuvant treatment should
be the achievement of better survival rates. Disappointingly, this
hypothesis is not supported by data found in the literature.16 There-
fore, there is nowgeneral agreement that large randomized trials to
compare up-front surgerywith neoadjuvant therapy before surgery
are warranted.
For patients with locally unresectable pancreatic cancer, poten-
tial tumor downsizing through chemoradiation promises to maxi-
mize the chance of a complete resection. However, the relatively
low rate of resection after treatment in this set of patients requiresvery candid discussions with patients regarding the goal of therapy.
In a recent meta-analysis,17 only 39% of all patients after neoadju-
vant treatment were surgically explored, but 72% of explored
patients underwent a successful pancreatic resection. These data
indicate two distinct anatomic sets among these patients:
a responding group that may beneﬁt from surgery, and a non-
responding group for which preoperative therapy is largely ineffec-
tive. How canwe explain this result? It can be consistently afﬁrmed
that the former group includes the vast majority of patients with
“borderline resectable cancers,” a distinct set whose management
should be considered separately from resectable cancers and
from those that are locally advanced. The largest study on patients
with borderline resectable disease published to date, by the M.D.
Anderson group,18 demonstrates the good results of neoadjuvant
treatment in this subset of patients.
In conclusion, pancreatic surgery has passed the test of time and
is now a safe and effective treatment modality for patients affected
by pancreatic cancer. However, pancreatic anastomotic ﬁstula
remains a major clinical problem requiring an evidence-based solu-
tion. A new method of pathological examination of the surgical
specimen has shown that R1 rate after pancreaticoduodenectomy
is signiﬁcantly higher than that reported in the literature. It is
now clear that at least 75% of our pancreaticoduodenectomies for
cancer cannot actually be considered radical, due to the presence
of cancer cells at the surgical margin. Surgical resection of patients
with portal vein or mesenteric vein inﬁltration is an effective treat-
mentmodality, but only selected patients with arterial involvement
would beneﬁt from surgical resection. Finally, neoadjuvant treat-
ment is the most promising therapeutic modality to improve
long-term results of our patients. Ongoing trials will soon deﬁne
this relevant topic.
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